SBI Okasan Asset Management Co.Ltd. Acquires New Position in Xenon Pharmaceuticals Inc. $XENE

SBI Okasan Asset Management Co.Ltd. bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 14,400 shares of the biopharmaceutical company’s stock, valued at approximately $638,000.

Several other large investors also recently added to or reduced their stakes in XENE. Goldman Sachs Group Inc. grew its position in Xenon Pharmaceuticals by 7.9% in the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after acquiring an additional 32,486 shares in the last quarter. Jump Financial LLC bought a new stake in Xenon Pharmaceuticals in the second quarter worth approximately $532,000. Sei Investments Co. bought a new stake in Xenon Pharmaceuticals in the second quarter worth approximately $711,000. The Manufacturers Life Insurance Company bought a new stake in Xenon Pharmaceuticals in the second quarter worth approximately $816,000. Finally, Alliancebernstein L.P. grew its position in Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock worth $47,530,000 after acquiring an additional 189,141 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on XENE shares. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Robert W. Baird raised their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $77.20.

Insider Activity at Xenon Pharmaceuticals

In related news, insider Andrea Difabio sold 2,607 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares in the company, valued at $294,118.23. This represents a 34.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $361,980. The trade was a 97.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 296,707 shares of company stock worth $17,845,365 in the last ninety days. 4.07% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $54.73 on Friday. The stock has a market cap of $5.29 billion, a P/E ratio of -11.64 and a beta of 0.65. Xenon Pharmaceuticals Inc. has a one year low of $28.19 and a one year high of $63.95. The company has a fifty day moving average price of $56.02 and a 200 day moving average price of $48.10.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting the consensus estimate of ($1.17). During the same quarter last year, the firm earned ($0.83) EPS. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.88 EPS for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.